SEC Form 4
Supernus Pharmaceuticals, Inc. (SUPN) insider trading
In the 12 months to Oct 26, 2026, 7 SUPN insiders reported open-market sales of $10.2M across 8 filings; no open-market purchases were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $10.2M
- 8 filings · 7 insiders
- Open-market purchases
- $0
- 0 filings
- Pre-arranged sales (10b5-1)
- 4 of 8
- $8.4M of $10.2M sold (82%)
Who traded SUPN, and when
- Sale
- Sale, pre-arranged (10b5-1)
SUPN daily close from Oct 27, 2025 to Oct 26, 2026, between $37.88 and $57.00, last $40.63. 8 sale and 0 purchase filings by 7 insiders, marked at their filing dates. Padmanabh P. Bhatt, Sr. VP of IP, CSO: sold $5.4M across 1 filing, first filed Mar 18, 2026, last Mar 18, 2026. Jack A. Khattar, President, CEO: sold $1.8M across 1 filing, first filed Mar 16, 2026, last Mar 16, 2026. Frank Mottola, SVP, Chief Tech. Ops. Officer: sold $1.1M across 2 filings, first filed Dec 22, 2025, last Mar 10, 2026. Georges Gemayel, Director: sold $1.0M across 1 filing, first filed Mar 9, 2026, last Mar 9, 2026. William Todd Horich, SVP, Commercial Operations: sold $483.8K across 1 filing, first filed Mar 10, 2026, last Mar 10, 2026. Frederick M. Hudson, Director: sold $271.7K across 1 filing, first filed Mar 16, 2026, last Mar 16, 2026. Bethany Sensenig, Director: sold $228.3K across 1 filing, first filed Feb 23, 2026, last Feb 23, 2026.
Largest mark · tap a row for others
Padmanabh P. Bhatt · Sr. VP of IP, CSO
Sale $5,388,432
107,250 shares at $50.24 avg
Filed Mar 18, 2026 · traded Mar 16
Pre-arranged (10b5-1) · close on filing date $49.29
Padmanabh P. Bhatt · Sr. VP of IP, CSO
Sr. VP of IP, CSO
$5.4M soldJack A. Khattar · President, CEO
President, CEO
$1.8M soldFrank Mottola · SVP, Chief Tech. Ops. Officer
SVP, Chief Tech. Ops. Officer
$1.1M soldGeorges Gemayel · Director
Director
$1.0M soldWilliam Todd Horich · SVP, Commercial Operations
SVP, Commercial Operations
$483.8K soldFrederick M. Hudson · Director
Director
$271.7K soldBethany Sensenig · Director
Director
$228.3K soldOpen-market trades
8 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Padmanabh P. Bhatt | Sr. VP of IP, CSO | $5.4M | — | 1 | 100% of sales | |
| Jack A. Khattar | President, CEO | $1.8M | — | 1 | 100% of sales | |
| Frank Mottola | SVP, Chief Tech. Ops. Officer | $1.1M | — | 2 | 92% of sales | |
| Georges Gemayel | Director | $1.0M | — | 1 | — | |
| William Todd Horich | SVP, Commercial Operations | $483.8K | — | 1 | — | |
| Frederick M. Hudson | Director | $271.7K | — | 1 | — | |
| Bethany Sensenig | Director | $228.3K | — | 1 | 100% of sales |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Padmanabh P. Bhatt Sr. VP of IP, CSO | SalePre-arranged (10b5-1) | 107,250 | $50.24 | $5.4M | 17,044 | |
traded | Frederick M. Hudson Director | Sale | 5,369 | $50.61 | $271.7K | 60,413 | |
traded | Jack A. Khattar President, CEO | SalePre-arranged (10b5-1) | 35,000 | $50.37 | $1.8M | 958,100 | |
traded | Frank Mottola SVP, Chief Tech. Ops. Officer | Sale | 1,623 | $53.65 | $87.1K | 18,440 | |
traded | William Todd Horich SVP, Commercial Operations | Sale | 8,877 | $54.50 | $483.8K | 0 | |
traded | Georges Gemayel Director | Sale | 18,787 | $53.38 | $1.0M | 27,277 | |
traded | Bethany Sensenig Director | SalePre-arranged (10b5-1) | 4,475 | $51.01 | $228.3K | 0 | |
traded | Frank Mottola SVP, Chief Tech. Ops. Officer | SalePre-arranged (10b5-1) | 20,000 | $50.41 | $1.0M | 15,496 |
GET /stocks/filings/vX/form-4?tickers=SUPN&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"SUPN"
],
"issuer_cik": "0001356576",
"owner_cik": "0001539215",
"accession_number": "0001539215-26-000008",
"form_type": "4",
"filing_date": "2026-03-18",
"period_of_report": "2026-03-16",
"issuer_name": "SUPERNUS PHARMACEUTICALS, INC.",
"issuer_trading_symbol": "SUPN",
"owner_name": "Bhatt Padmanabh P.",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "Sr. VP of IP, CSO",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-03-16",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 34114,
"transaction_price_per_share": 50.18,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 32930,
"transaction_value": 1711840.52,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "Transaction made pursuant to a 10b5-1 trading plan adopted December 12, 2025."
},
{
"id": "F2",
"description": "The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.34 to $50.34. The Reporting Person undertakes to provide to\nSupernus Pharmaceuticals, Inc. (\"Supernus\"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold\nat each separate price within the range set forth in this footnote to this Form 4."
}
]
},
{
"tickers": [
"SUPN"
],
"issuer_cik": "0001356576",
"owner_cik": "0001539215",
"accession_number": "0001539215-26-000008",
"form_type": "4",
"filing_date": "2026-03-18",
"period_of_report": "2026-03-16",
"issuer_name": "SUPERNUS PHARMACEUTICALS, INC.",
"issuer_trading_symbol": "SUPN",
"owner_name": "Bhatt Padmanabh P.",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "Sr. VP of IP, CSO",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-03-17",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 22290,
"transaction_price_per_share": 50.73,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 17044,
"transaction_value": 1130771.7,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "Transaction made pursuant to a 10b5-1 trading plan adopted December 12, 2025."
},
{
"id": "F5",
"description": "The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.40 to $51.15. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 79 records
- Option exercises28 records
- Tax withholding28 records
- Tax withholding (sold to cover)1 record
- Grants and awards20 records
- Other2 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has Supernus Pharmaceuticals, Inc.'s CEO sold stock?
Yes. Jack A. Khattar (CEO) sold 35,000 shares ($1.8M) in Mar 2026, all under a pre-arranged 10b5-1 plan.
How current is SUPN’s insider data?
These are SUPN Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track SUPN insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for SUPN every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.